Australian inflammatory diseases specialist Dimerix has received an initial payment of 6.5 million euros ($7 million) in line with the recently-announced licens 6 November 2023
The American business of Israeli drugmaker Teva Pharmaceutical has announced new Huntington’s disease (HD) data to be presented at the ongoing Huntington Study 3 November 2023
Swiss pharma giant Novartis has announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study of atrasentan, an oral 30 October 2023
In briefing notes released ahead of a key meeting on Tuesday, scientists at the US Food and Drug Administration describe uncertainty in the risks associated wit 30 October 2023
In a third-quarter financial results season when most pharma companies have pleased shareholders with better-than-expected figures, the reaction to Sanofi’s pre 27 October 2023
Tokyo-headquartered pharma major Takeda has announced results for the first half of its fiscal year, which in Japan runs from 1 April to 1 September. 27 October 2023
Privately-held gene editing company Verve Therapeutics has been cleared by the US regulator to go ahead with what will be the first in-human base editing study 26 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.